Akagera Medicines Inc

Akagera Medicines Inc. is a small biotechnology company headquartered in Boston, Massachusetts. With five employees, the company is focused on developing innovative solutions to combat tuberculosis (TB). Founded in 2018, Akagera Medicines is majority-owned by the people of Rwanda and operates laboratories in both Boston and San Francisco. The company specializes in creating novel liposomal formulations of antibacterial drugs for the treatment of TB. Akagera Medicines aims to improve the efficacy and shorten the duration of TB treatment while minimizing toxicity and cost for patients and society. Their approach has the potential to be applied to other infectious diseases such as MRSA, Malaria, and HIV. Akagera Medicines is driven by a strong moral purpose: to create medicines that will lead to a world free of TB. They intend to achieve this goal through several initiatives, including initiating clinical trials in humans by 2022, reducing global TB deaths by 80% in the next decade, eradicating multi-drug resistant TB, and ensuring treatments for various infectious diseases can be developed, tested, and manufactured in Africa. Akagera Medicines can be reached online at akageramedicines.com.